Table 1 Participating centres (number of patients, %) in the development and validation cohorts

From: Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration

Centre

N (%)

Development cohort

Alexandra

66 (39)

Papageorgiou

40 (24)

Othera

64 (37)

Total

170 (100)

Validation cohort

HEGP

90 (34)

KUL

96 (36)

IGR

63 (24)

Strasburg

17 (6)

Total

266 (100)

  1. aSeven centres with fewer than 15 patients each.
Back to article page